S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
How major US stock indexes fared Friday 6/2/2023
Closing prices for crude oil, gold and other commodities
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Lululemon, Five Below rise; Guidewire Software, PagerDuty fall
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Court battle over interstate travel targets Utah bus stops in Nevada, California
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
How major US stock indexes fared Friday 6/2/2023
Closing prices for crude oil, gold and other commodities
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Lululemon, Five Below rise; Guidewire Software, PagerDuty fall
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Court battle over interstate travel targets Utah bus stops in Nevada, California
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
How major US stock indexes fared Friday 6/2/2023
Closing prices for crude oil, gold and other commodities
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Lululemon, Five Below rise; Guidewire Software, PagerDuty fall
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Court battle over interstate travel targets Utah bus stops in Nevada, California
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
How major US stock indexes fared Friday 6/2/2023
Closing prices for crude oil, gold and other commodities
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Attorney says West Virginia governor refusing to pay judgment in coal lawsuit
Lululemon, Five Below rise; Guidewire Software, PagerDuty fall
[Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Court battle over interstate travel targets Utah bus stops in Nevada, California

Nevro (NVRO) Stock Forecast, Price & News

$28.27
+0.84 (+3.06%)
(As of 06/2/2023 ET)
Compare
Today's Range
$27.20
$28.42
50-Day Range
$26.04
$39.32
52-Week Range
$25.82
$53.34
Volume
439,169 shs
Average Volume
441,676 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.09

Nevro MarketRank™ Forecast

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
45.4% Upside
$41.09 Price Target
Short Interest
Healthy
4.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Nevro in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.45) to ($1.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

435th out of 983 stocks

Surgical & Medical Instruments Industry

44th out of 98 stocks


NVRO stock logo

About Nevro (NYSE:NVRO) Stock

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Stock News Headlines

Nevro (NYSE:NVRO) Shares Gap Up to $26.04
Royal Bank of Canada Initiates Coverage on Nevro (NYSE:NVRO)
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Nevro to Present at Jefferies Healthcare Conference
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Nevro (NYSE:NVRO) Now Covered by Analysts at StockNews.com
Oppenheimer Upgrades Nevro (NVRO)
Oppenheimer Upgrades Nevro (NYSE:NVRO) to "Outperform"
Nevro (NYSE:NVRO) Hits New 12-Month Low at $26.43
Nevro (NYSE:NVRO) Shares Gap Down After Analyst Downgrade
See More Headlines

NVRO Price History

NVRO Company Calendar

Last Earnings
4/26/2023
Today
6/03/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,087
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.09
High Stock Price Forecast
$72.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+45.4%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

Net Income
$3 million
Pretax Margin
0.89%

Debt

Sales & Book Value

Annual Sales
$406.36 million
Book Value
$8.41 per share

Miscellaneous

Free Float
34,742,000
Market Cap
$1.01 billion
Optionable
Optionable
Beta
0.88

Key Executives

  • D. Keith GrossmanD. Keith Grossman
    Chairman, President & Chief Executive Officer
  • Bryan Hix
    Vice President-Commercial Operations
  • Roderick H. MacLeod
    Chief Financial Officer & Senior Vice President
  • David Caraway
    Chief Medical Officer & Senior Vice President
  • Christopher Christoforou
    Senior Vice President-Technical Operations













NVRO Stock - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price forecast for 2023?

12 Wall Street analysts have issued 1 year target prices for Nevro's shares. Their NVRO share price forecasts range from $31.00 to $72.00. On average, they predict the company's share price to reach $41.09 in the next year. This suggests a possible upside of 45.4% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2023?

Nevro's stock was trading at $39.60 at the beginning of 2023. Since then, NVRO shares have decreased by 28.6% and is now trading at $28.27.
View the best growth stocks for 2023 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its quarterly earnings results on Wednesday, April, 26th. The medical equipment provider reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. The medical equipment provider had revenue of $96.33 million for the quarter, compared to analyst estimates of $95.35 million. Nevro had a net margin of 0.55% and a negative trailing twelve-month return on equity of 34.61%. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.98) earnings per share.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its second quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $110.00 million-$112.00 million, compared to the consensus revenue estimate of $111.52 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.88%), ArrowMark Colorado Holdings LLC (3.72%), Fred Alger Management LLC (3.28%), State Street Corp (2.58%), Geode Capital Management LLC (1.84%) and Principal Financial Group Inc. (1.81%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $28.27.

How much money does Nevro make?

Nevro (NYSE:NVRO) has a market capitalization of $1.01 billion and generates $406.36 million in revenue each year. The medical equipment provider earns $3 million in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Nevro have?

The company employs 1,087 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.

This page (NYSE:NVRO) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -